Talsaclidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Talsaclidine
DrugBank Accession Number
DB12287
Background

Talsaclidine has been used in trials studying the treatment of Alzheimer Disease.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 165.236
Monoisotopic: 165.115364107
Chemical Formula
C10H15NO
Synonyms
  • Talsaclidine

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as quinuclidines. These are compounds containing a 1-azabicyclo[2.2.2]octane moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinuclidines
Sub Class
Not Available
Direct Parent
Quinuclidines
Alternative Parents
Piperidines / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Acetylides / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Acetylide / Aliphatic heteropolycyclic compound / Amine / Azacycle / Dialkyl ether / Ether / Hydrocarbon derivative / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
1O8VSL798T
CAS number
147025-53-4
InChI Key
XVFJONKUSLSKSW-JTQLQIEISA-N
InChI
InChI=1S/C10H15NO/c1-2-7-12-10-8-11-5-3-9(10)4-6-11/h1,9-10H,3-8H2/t10-/m0/s1
IUPAC Name
(3R)-3-(prop-2-yn-1-yloxy)-1-azabicyclo[2.2.2]octane
SMILES
C#CCO[C@H]1CN2CCC1CC2

References

General References
Not Available
PubChem Compound
71792
PubChem Substance
347828555
ChemSpider
64819
BindingDB
50119648
ChEMBL
CHEMBL2111051
ZINC
ZINC000001547638
Wikipedia
Talsaclidine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAlzheimer's Disease (AD)1
2TerminatedTreatmentAlzheimer's Disease (AD)1
2, 3TerminatedTreatmentAlzheimer's Disease (AD)1
1CompletedTreatmentHealthy Volunteers (HV)4

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.666 mg/mLALOGPS
logP1.02ALOGPS
logP0.73Chemaxon
logS-2.4ALOGPS
pKa (Strongest Basic)8.76Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area12.47 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity48.56 m3·mol-1Chemaxon
Polarizability18.86 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-03di-5900000000-d44167244a04ec24bfc8
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0900000000-1b9156bd3eb4b48e1b5c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-2900000000-cbe41b437c0262221d18
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0900000000-3cefb2e64f028afe9707
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0bt9-7900000000-4181166e91d6a35fd85e
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-08fr-0900000000-de2abdac214e2efbae0f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-4900000000-f0f016b2b11b86a43f9e
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-136.3889286
predicted
DarkChem Lite v0.1.0
[M-H]-133.54744
predicted
DeepCCS 1.0 (2019)
[M+H]+136.9231286
predicted
DarkChem Lite v0.1.0
[M+H]+136.31847
predicted
DeepCCS 1.0 (2019)
[M+Na]+136.8241286
predicted
DarkChem Lite v0.1.0
[M+Na]+145.14787
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 21:50 / Updated at February 21, 2021 18:53